<DOC>
	<DOCNO>NCT01599429</DOCNO>
	<brief_summary>Positron emission tomography use various radioactive tracer measure metabolic activity none-invasive way , specially follow activity disease treatment . Among new tracer , fluorothymidine ( 18F-FLT ) arouse lot interest . This new tool would allow image follow time wise acute myeloid leukemia ( AML ) . The investigator want , ( 18F-FLT ) , characterise aggressivity tumor prognostic chemotherapy treatment . The aim study able identify earlier responder , detect sooner , patient benefit aggressive treatment .</brief_summary>
	<brief_title>Study Predictive Marker FLT Patients Suffering From AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Patients 18 year time inclusion ; 2 . Patients newly diagnose acute myeloid leukemia ; 3 . No contraindication intolerance component standard chemotherapy induction ( 7+3 ) ; 4 . Patients able give write informed consent . 1 . Patients unable tolerate decubitus position least 45 minute ; 2 . Any previous neoplasia neoplasia simultaneously ; 3 . Previously treat buy radiotherapy , bone marrow field radiation ; 4 . Other chemotherapy treatment standard chemotherapy induction ( 7+3 ) , second FLTTEP do .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>AML / LMA</keyword>
</DOC>